These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 845271)

  • 1. Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function.
    Boughton BJ; Corbett WE; Ginsburg AD
    J Clin Pathol; 1977 Mar; 30(3):228-34. PubMed ID: 845271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.
    Baker RI; Manoharan A
    Eur J Haematol; 1988 Mar; 40(3):267-72. PubMed ID: 3356243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders: deficiency of an aspirin-independent mechanism?
    Viero P; Cortelazzo S; Barbui T; de Gaetano G
    Haemostasis; 1986; 16(1):27-33. PubMed ID: 3699584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder.
    Handa M; Watanabe K; Kawai Y; Kamata T; Koyama T; Nagai H; Ikeda Y
    Thromb Haemost; 1995 Mar; 73(3):521-8. PubMed ID: 7667837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
    Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
    Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The platelet defect in myeloproliferative disorder (author's transl)].
    Delobel J
    Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders.
    Nishimura J; Okamoto S; Ibayashi H
    Thromb Haemost; 1979 Jun; 41(4):787-95. PubMed ID: 483250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
    Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
    Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic myeloproliferative disorders: a quantitative assessment of platelet ultrastructure.
    Boughton BJ; Jerrome DW; Rychetnik M
    Acta Haematol; 1980; 64(6):319. PubMed ID: 6782797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders.
    Bolin RB; Okumura T; Jamieson GA
    Am J Hematol; 1977; 3():63-71. PubMed ID: 602945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies.
    Manoharan A; Gemmell R; Brighton T; Dunkley S; Lopez K; Kyle P
    Br J Haematol; 1999 Jun; 105(3):618-25. PubMed ID: 10354122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
    Hochhaus A; Mindner K; Ostermann G; Höche D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):765-70. PubMed ID: 1713878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal platelet function in myeloproliferative disorders.
    Waddell CC; Brown JA; Repinecz YA
    Arch Pathol Lab Med; 1981 Aug; 105(8):432-5. PubMed ID: 6894852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet function studies in myeloproliferative disorders.
    Pfliegler G; Boda Z; Udvardy M; Kiss A; Telek B; Pecze K; Nagy P; Rak K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):655-62. PubMed ID: 2435631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.